Atlas Trials

A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2

Clinical trial NCT05911087 · UNKNOWN

Trial details

NCT number
NCT05911087
Sponsor
Stemirna Therapeutics
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
ImmunogenicitySafety
Start date
2023-06-20
Primary completion
2023-07-31
Enrollment
800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.